Impact of Disclosure of HIV Infection on Health-Related Quality of Life Among Children and Adolescents With HIV Infection

Butler, Anne M.; Williams, Paige L.; Howland, Lois C.; Storm, Deborah S.; Hutton, Nancy; Seage, George R.

doi:10.1542/peds.2008-1290

Cited by 102 publications

(100 citation statements)

References 29 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Increasingly, clinicians now address issues of disclosure at an earlier age than previously 99, with awareness that early, general discussions focusing on healthy diet and lifestyle and knowledge about the blood and immune system can provide a useful foundation for later, specific discussions about HIV. It will generally be appropriate for most children to know their HIV status (i.e.…”

Section: Adherence and Hiv Knowledgementioning

confidence: 99%

Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV‐1 infection 2015: optimizing health in preparation for adult life

et al. 2015

View full text Add to dashboard Cite

The 2015 Paediatric European Network for Treatment of AIDS (PENTA) guidelines provide practical recommendations on the management of HIV‐1 infection in children in Europe and are an update to those published in 2009. Aims of treatment have progressed significantly over the last decade, moving far beyond limitation of short‐term morbidity and mortality to optimizing health status for adult life and minimizing the impact of chronic HIV infection on immune system development and health in general. Additionally, there is a greater need for increased awareness and minimization of long‐term drug toxicity. The main updates to the previous guidelines include: an increase in the number of indications for antiretroviral therapy (ART) at all ages (higher CD4 thresholds for consideration of ART initiation and additional clinical indications), revised guidance on first‐ and second‐line ART recommendations, including more recently available drug classes, expanded guidance on management of coinfections (including tuberculosis, hepatitis B and hepatitis C) and additional emphasis on the needs of adolescents as they approach transition to adult services. There is a new section on the current ART ‘pipeline’ of drug development, a comprehensive summary table of currently recommended ART with dosing recommendations. Differences between PENTA and current US and World Health Organization guidelines are highlighted and explained.

show abstract

Section: Adherence and Hiv Knowledgementioning

confidence: 99%

Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV‐1 infection 2015: optimizing health in preparation for adult life

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The raw scores in all seven domains had different minimum and maximum values, therefore, the raw scores were calculated to simple transformed scores of 0 to 100 with the following formula: transformed score = [(actual raw score -lowest possible raw score)/ (highest possible raw score -lowest possible raw score)] · 100]. 3,10,13,19 For items with mixed or negative directionality, scores were reverse coded so that higher scores indicated higher QOL. 3,10,13 …”

Section: Quality Of Life Questionnaire and Transformed Scoresmentioning

confidence: 99%

“…3,10,13,19 For items with mixed or negative directionality, scores were reverse coded so that higher scores indicated higher QOL. 3,10,13 …”

Section: Quality Of Life Questionnaire and Transformed Scoresmentioning

confidence: 99%

“…The majority of QOL reports in HIV-infected children were from resource-rich settings, and conducted as cross-sectional studies in children already treated with ART. 3,[10][11][12] There are limited data of QOL change before and after ART initiation in HIV-infected children without AIDS symptoms. 13 Our team has conducted a multicenter, randomized, openlabel study of early versus deferred ART among Thai and Cambodian ART-naïve HIV-infected children with CD4 15-24% (Pediatric Randomized of Early vs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Antiretroviral Therapy on Quality of Life in HIV-Infected Southeast Asian Children in the PREDICT Study

Bunupuradah

Kosalaraksa²,

Vibol³

et al. 2013

AIDS Patient Care and STDs

View full text Add to dashboard Cite

Quality of life (QOL) is an important antiretroviral treatment (ART) outcome. We compared QOL among 299 Thai and Cambodian children ages 1-12 years-old, CD4 15-24% randomized to early (ART at week 0, N = 149) versus deferred groups (ART when at CD4 < 15%, N = 150) and also compared with QOL data from age-matched healthy controls (N = 275). Primary caregivers completed PACTG QOL questionnaires at week 0 and every 24 weeks until 144 weeks. Children were enrolled during March 2006 to September 2008. Mean (SD) age of children was 6.3 (2.8) years, 58% were female, 60% were Thai, %CDC N:A:B:C was 2:62:36:0%. During 144 weeks, all children in the early-group and 69 (46%) of deferred-group children started ART. There was no significant difference of QOL scores between treatment groups at baseline (all p > 0.05) and at week 144 (all p > 0.05). By multivariate analysis, the early-group had higher QOL score changes in five domains, including health perception ( p = 0.04), physical resilience ( p = 0.02), psychosocial well-being ( p = 0.04), social and role functioning ( p < 0.01), and symptoms ( p = 0.01) compared to the deferred group. QOL of HIV-infected children in both groups were lower than healthy control in all 7 domains at baseline (all p < 0.05) and 5 of 7 domains at weeks 144 ( p < 0.01). In conclusion, no significant difference of QOL scores between treatment groups. Early ART commencement associated with greater increase of QOL scores over 144 weeks. QOL scores in HIV-infected children were lower than healthy controls.

show abstract

“…A study reported in 2008 that women are interested in taking a leading role in the disclosure of perinatally acquired HIV infection to children and youth ages 5 to 18 years [14]. The possible parental concern that disclosure could interfere with Julio's quality of life could have been discussed with reference to results from a study among children and adolescents with perinatally acquired HIV infection, which showed no statistically significant differences between pre-disclosure and post-disclosure quality of life [15].…”

Section: Commentarymentioning

confidence: 99%

Informing Adolescents of Perinatally Contracted HIV

Spiegel

Futterman²

2009

AMA Journal of Ethics

View full text Add to dashboard Cite

Impact of Disclosure of HIV Infection on Health-Related Quality of Life Among Children and Adolescents With HIV Infection

Abstract: Background-Little is known concerning the impact of HIV status disclosure on quality of life, leaving clinicians and families to rely on research of children with other terminal illnesses.

Cited by 102 publications

References 29 publications

Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV‐1 infection 2015: optimizing health in preparation for adult life

Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV‐1 infection 2015: optimizing health in preparation for adult life

Impact of Antiretroviral Therapy on Quality of Life in HIV-Infected Southeast Asian Children in the PREDICT Study

Informing Adolescents of Perinatally Contracted HIV

Contact Info

Product

Resources

About